Navigation Links
Argos Therapeutics' Arcelis™ Immunotherapy for the Treatment of Renal Cell Carcinoma (RCC) in Combination With Sunitinib Demonstrates Strong Immunologic Response That Correlates to Improved Clinical Outcomes
Date:6/1/2011

DURHAM, N.C., June 1, 2011 /PRNewswire/ -- Argos Therapeutics announced today that its Arcelis™ immunotherapy for the treatment of renal cell carcinoma (RCC), AGS-003, in combination with sunitinib demonstrated a strong immunologic response that correlated to improved clinical outcomes. The Phase 2 combination study in newly diagnosed, metastatic RCC patients with unfavorable prognosis demonstrated decreases in T regulatory cells, along with a concurrent expansion of CD28+memory cytotoxic T lymphocytes (CTL). Results will be presented by Dr. Robert Figlin, director of the Division of Hematology/Oncology at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, in a poster and a discussion session at 8 a.m. CDT, and noon CDT, respectively, Saturday, June 4, 2011, at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

The study is the first to demonstrate the combined immunologic and clinical effects of AGS-003, or any active immunotherapy, with sunitinib. Most patients experienced reversal of baseline tumor-induced immunosuppression and showed improved progression-free survival (PFS) compared to the expected PFS with sunitinib alone in an unfavorable risk, metastatic RCC patient population. Assessment of immunodynamicsusing multiparametric flow cytometry was performed on peripheral blood mononuclear cells isolated from blood draws collected prior to treatment and after treatment with AGS-003 during combination administration with sunitinib. Nine of 11 patients with PFS of >10 months demonstrated CTL population increases whereas two of four patients with PFS <10 months showed increases in this specific CTL population. Updates on the correlation between prolonged PFS and CTL expansion will be presented during ASCO.

"The study provides initial evidence that AGS-003
'/>"/>

SOURCE Argos Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Interleukin (IL)-12 Secretion Can Predict Potency of Argos Therapeutics Arcelis™ Dendritic Cell (DC) Immunotherapy and Can Be Used as Potency Marker in Phase 3 Clinical Trial
2. Argos Therapeutics to Present Potential of its Arcelis™ Immunotherapy as an Innovative, Effective Treatment for HIV at the APHA 138th Annual Meeting & Exposition
3. Argos Therapeutics to Present Overview of its Arcelis™ Dendritic Cell-based Immunotherapy, Participate in Panel Discussion at Inaugural Cancer Immunotherapy Conference
4. Argos Therapeutics to Present Recent Clinical Developments and Corporate Overview at 18th Annual BioPartnering Europe
5. Results From Argos Therapeutics Arcelis™ Immunotherapy Phase 2 Study for Treatment of Renal Cell Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium
6. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2011 Global Healthcare Conference in New York
7. Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017
8. Reportlinker Adds Myelodysplastic Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2017
9. Cell Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Rule
10. Amicus Therapeutics to Present at Jefferies 2011 Global Healthcare Conference on Tuesday, June 7, 2011
11. Reportlinker Adds Risk Evaluation and Mitigation Strategy (REMS) - Opioids, Erythropoesis-Stimulating Agents and Cancer Therapeutics are the Most Important Classes That Require REMS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 26, 2014  BioScrip ® , Inc. (NASDAQ: ... , President and Chief Executive Officer, will present at the Bank ... , , , Date: , , , Wednesday, December ... 2:50 p.m. EST , , , , Location: , , ... About BioScrip, Inc. BioScrip, Inc. ...
(Date:11/26/2014)... 2014  CARsgen, a leader in the development of ... a variety of cancers, today announced the completion of ... China -based healthcare private equity fund.   ... the development of new therapeutics for liver, lung, stomach ... and Shanghai Renji Hospital, the company plans to initiate ...
(Date:11/26/2014)... and LONDON , Nov. ... market intelligence, MarketResearch.com is pleased to announce the distribution ... Consultancy focusing on the active pharmaceutical ingredient (API) market. ... http://www.marketresearch.com/land/publisher.asp?vendorid=4023&progid=86891 . In IQ4I,s newest ... Forecast to 2020 , IQ4I analysts ...
Breaking Medicine Technology:CARsgen Completes Series A Financing 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3
... on unmet needs of the lumbar ... ... CoreSpine Technologies, LLC, an,emerging spinal device company announced today the ... application,for minimally invasive fusion., The development of CoreSpine,s Technologies, initial ...
... Developer of Antibody Technologies to Strengthen Management Team, ... sheets: MNCN), a manufacturer and distributor of products,for animal ... Nash,Ph.D. as Chief Scientific Officer., In his new ... development activities in innovative antibody technologies for use in,the ...
Cached Medicine Technology:CoreSpine Technologies Expands Spinal Disc Site Preparation Efforts 2Dr. Peter Nash, Ph.D. Joins Mach One Corporation as Chief Scientist 2
(Date:11/26/2014)... WEDNESDAY, Nov. 26, 2014 (HealthDay News) -- When ... factor high altitude into your vacation sports -- ... specialist cautions. Outdoor explorers may fail ... recreation areas, which puts them at risk of ... high above sea level, according to Dr. Melissa ...
(Date:11/26/2014)... Steven Reinberg HealthDay Reporter ... adults are smoking cigarettes than ever, health officials said. ... about 21 percent in 2005 to 18 percent in 2013. ... million to 42.1 million, despite the increasing population, according to ... However,"we still have a long way to go, and ...
(Date:11/26/2014)... The family foundation of Best Buy founder, ... Research Foundation (Meso Foundation), half of which will be ... Grant Program . The focus area of the Richard ... with organizations that can generate transformational results in education, ... founder and chairman emeritus of Best Buy Co., Inc., ...
(Date:11/26/2014)... November 26, 2014 The American ... the Association’s new director of meetings and conferences. ... annual meeting, special events and conferences. , ... this post,” said AAA Executive Director Ed Liebow. ... enthusiasm and energy. She was recognized in January ...
(Date:11/26/2014)... DC (PRWEB) November 26, 2014 For ... (AIS) independently published The AIS Report on Blue Cross ... and WellPoint, Inc. on the varied strategies the two ... and improve compliance with treatments for sleep apnea, ranging ... sleep disorder, because it’s linked to increased rates of ...
Breaking Medicine News(10 mins):Health News:Don't Let High Altitude Ruin Your Holiday Trip 2Health News:U.S. Adult Smoking Rate Drops to New Low: CDC 2Health News:U.S. Adult Smoking Rate Drops to New Low: CDC 3Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 2Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 3Health News:American Anthropological Association Appoints New Director of Meetings and Conferences: Ushma Suvarnakar 2Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 2Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 3
... , THURSDAY, June 3 (HealthDay News) -- Fatal medication ... of the inexperience of new medical residents, a new ... July, and those first weeks may be a dangerous ... the University of California, San Diego. , The ...
... others say it,s not always that simple, , THURSDAY, June ... anxiety in many a parent. But having to incorporate ... can make an already sensitive subject even more complicated. , ... , As assisted reproduction technology, in which someone other than ...
... ... Salt Lake Host Malaria Awareness Soccer Clinic this Thursday for Local Youth as part of ... ... and the United Nations Foundation ’s Nothing But Nets campaign are teaming up to ...
... ... ongoing market research study that provides detailed analyses on health plans’ coverage and ... ... (HIRC) Specialty Pharmaceuticals Service is an ongoing market research study that provides detailed ...
... fish appears to lessen likelihood of wheeze, study finds ... eat three or more hamburgers a week may raise their ... However, eating the so-called "Mediterranean diet" -- rich in fruits, ... researchers say. , "Our results support previous reports that the ...
... have a different chemical fingerprint in their urine than non-autistic ... edition of the Journal of Proteome Research . ... the University of South Australia, suggest that their findings could ... or not a young child has autism. Autism ...
Cached Medicine News:Health News:Donor-Assisted Conception Sparks Disclosure Dilemmas 2Health News:Donor-Assisted Conception Sparks Disclosure Dilemmas 3Health News:Real Salt Lake Teams Up with Nothing But Nets to Fight Malaria 2Health News:Real Salt Lake Teams Up with Nothing But Nets to Fight Malaria 3Health News:HIRC Research Alert: Health Plans Expected to Increase Adoption of Percent Copays to Manage Specialty Medications 2Health News:HIRC Research Alert: Health Plans Expected to Increase Adoption of Percent Copays to Manage Specialty Medications 3Health News:Burgers May Feed Kids' Asthma Risk 2Health News:Burgers May Feed Kids' Asthma Risk 3Health News:Autism finding could lead to simple urine test for the condition 2Health News:Autism finding could lead to simple urine test for the condition 3
The Universal Knee Positioner(s)™ reduces surgeon fatigue while assisting in the stabilization of a patient's leg during surgury....
... Like other blood salvage devices, the Haemonetics ... cells lost during and after surgery, but ... kind designed specifically to adapt to the ... patients. The system consists of single-patient use ...
... The MicroAire® Hi Speed Pulse Lavage ... bone surfaces as well as cleansing ... Now a great system just got ... effective with the addition of ...
... a complete system of surgical instruments and ... fusion surgery. The system was designed in ... research and engineering with advanced materials, techniques ... different, and because the anatomy of the ...
Medicine Products: